RU2006102127A - Производные хинолина и их применение в терапии - Google Patents
Производные хинолина и их применение в терапии Download PDFInfo
- Publication number
- RU2006102127A RU2006102127A RU2006102127/04A RU2006102127A RU2006102127A RU 2006102127 A RU2006102127 A RU 2006102127A RU 2006102127/04 A RU2006102127/04 A RU 2006102127/04A RU 2006102127 A RU2006102127 A RU 2006102127A RU 2006102127 A RU2006102127 A RU 2006102127A
- Authority
- RU
- Russia
- Prior art keywords
- formula
- group
- compound
- chloro
- quinolinyl
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title claims 2
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 40
- 229910052736 halogen Inorganic materials 0.000 claims 21
- 150000002367 halogens Chemical class 0.000 claims 20
- 125000001424 substituent group Chemical group 0.000 claims 20
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 19
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 239000001257 hydrogen Substances 0.000 claims 18
- 229910052757 nitrogen Inorganic materials 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 13
- 239000012453 solvate Substances 0.000 claims 13
- -1 C 1 -C 6 alkoxy Chemical group 0.000 claims 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 11
- 125000000623 heterocyclic group Chemical group 0.000 claims 10
- 229910052760 oxygen Inorganic materials 0.000 claims 9
- 229910052717 sulfur Chemical group 0.000 claims 9
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 7
- 125000005842 heteroatom Chemical group 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 7
- 239000001301 oxygen Chemical group 0.000 claims 7
- 239000011593 sulfur Chemical group 0.000 claims 7
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 5
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 4
- 125000004122 cyclic group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 3
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 230000000414 obstructive effect Effects 0.000 claims 3
- 208000023504 respiratory system disease Diseases 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- QLWVEYMPLVEDGZ-MRXNPFEDSA-N (3r)-n-(6-chloro-2-piperazin-1-ylquinolin-5-yl)-3-phenylbutanamide Chemical compound C([C@@H](C)C=1C=CC=CC=1)C(=O)NC(C1=CC=2)=C(Cl)C=CC1=NC=2N1CCNCC1 QLWVEYMPLVEDGZ-MRXNPFEDSA-N 0.000 claims 1
- QBBJXWLPTPKFRD-WBVHZDCISA-N (3r)-n-[2-[(3s)-3-aminopyrrolidin-1-yl]-6-chloroquinolin-5-yl]-3-phenylbutanamide Chemical compound C([C@@H](C)C=1C=CC=CC=1)C(=O)NC(C1=CC=2)=C(Cl)C=CC1=NC=2N1CC[C@H](N)C1 QBBJXWLPTPKFRD-WBVHZDCISA-N 0.000 claims 1
- KUAGIPCPUKVKDX-QUCCMNQESA-N (3r)-n-[6-chloro-2-[(3s)-3-(3-hydroxypropylamino)pyrrolidin-1-yl]quinolin-5-yl]-3-phenylbutanamide Chemical compound C([C@@H](C)C=1C=CC=CC=1)C(=O)NC(C1=CC=2)=C(Cl)C=CC1=NC=2N1CC[C@H](NCCCO)C1 KUAGIPCPUKVKDX-QUCCMNQESA-N 0.000 claims 1
- UFXQGZOKXNJGEG-GOSISDBHSA-N (3r)-n-[6-chloro-2-[3-(3-hydroxypropylamino)propyl]quinolin-5-yl]-3-phenylbutanamide Chemical compound C1([C@@H](CC(=O)NC=2C3=CC=C(CCCNCCCO)N=C3C=CC=2Cl)C)=CC=CC=C1 UFXQGZOKXNJGEG-GOSISDBHSA-N 0.000 claims 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 1
- NCJPBVDUTKJDMQ-UHFFFAOYSA-N 1-[6-chloro-5-(2,2-diphenylethylcarbamoyl)quinolin-2-yl]piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C1=CC=C(C(C(=O)NCC(C=2C=CC=CC=2)C=2C=CC=CC=2)=C(Cl)C=C2)C2=N1 NCJPBVDUTKJDMQ-UHFFFAOYSA-N 0.000 claims 1
- KCWSDKICODBYRE-UHFFFAOYSA-N 1-[6-chloro-5-(2-phenylethylcarbamoyl)quinolin-2-yl]piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C1=CC=C(C(C(=O)NCCC=2C=CC=CC=2)=C(Cl)C=C2)C2=N1 KCWSDKICODBYRE-UHFFFAOYSA-N 0.000 claims 1
- GSAGYAQILPUYNV-UHFFFAOYSA-N 1-[6-chloro-5-[2-(2,6-dichlorophenyl)ethylcarbamoyl]quinolin-2-yl]piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C1=CC=C(C(C(=O)NCCC=2C(=CC=CC=2Cl)Cl)=C(Cl)C=C2)C2=N1 GSAGYAQILPUYNV-UHFFFAOYSA-N 0.000 claims 1
- CRJDINJRUVRMOC-UHFFFAOYSA-N 1-[6-chloro-5-[2-(2-chlorophenyl)ethylcarbamoyl]quinolin-2-yl]piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C1=CC=C(C(C(=O)NCCC=2C(=CC=CC=2)Cl)=C(Cl)C=C2)C2=N1 CRJDINJRUVRMOC-UHFFFAOYSA-N 0.000 claims 1
- WNYZCFCQFZXZHF-UHFFFAOYSA-N 1-[6-chloro-5-[2-(2-fluorophenyl)ethylcarbamoyl]quinolin-2-yl]piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C1=CC=C(C(C(=O)NCCC=2C(=CC=CC=2)F)=C(Cl)C=C2)C2=N1 WNYZCFCQFZXZHF-UHFFFAOYSA-N 0.000 claims 1
- YWQHIVPXCXZJRT-UHFFFAOYSA-N 1-[6-chloro-5-[2-(2-methylphenyl)ethylcarbamoyl]quinolin-2-yl]piperidine-4-carboxylic acid Chemical compound CC1=CC=CC=C1CCNC(=O)C1=C(Cl)C=CC2=NC(N3CCC(CC3)C(O)=O)=CC=C12 YWQHIVPXCXZJRT-UHFFFAOYSA-N 0.000 claims 1
- PPDLJZBXSGMJNN-UHFFFAOYSA-N 1-[6-chloro-5-[2-(4-chlorophenyl)ethylcarbamoyl]quinolin-2-yl]piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C1=CC=C(C(C(=O)NCCC=2C=CC(Cl)=CC=2)=C(Cl)C=C2)C2=N1 PPDLJZBXSGMJNN-UHFFFAOYSA-N 0.000 claims 1
- SNZIFZIIBGBVAZ-UHFFFAOYSA-N 1-[6-chloro-5-[3-(2-chlorophenyl)propanoylamino]quinolin-2-yl]piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C1=CC=C(C(NC(=O)CCC=2C(=CC=CC=2)Cl)=C(Cl)C=C2)C2=N1 SNZIFZIIBGBVAZ-UHFFFAOYSA-N 0.000 claims 1
- VHWQUGFTNYMILN-HNNXBMFYSA-N 2-[(3s)-3-aminopyrrolidin-1-yl]-6-chloro-n-[2-(2-chlorophenyl)ethyl]quinoline-5-carboxamide Chemical compound C1[C@@H](N)CCN1C1=CC=C(C(C(=O)NCCC=2C(=CC=CC=2)Cl)=C(Cl)C=C2)C2=N1 VHWQUGFTNYMILN-HNNXBMFYSA-N 0.000 claims 1
- QPJLXQIFYVOTGJ-UHFFFAOYSA-N 3-(3,4-dichlorophenyl)-2-methyl-n-quinolin-5-ylpropanamide Chemical compound C=1C=CC2=NC=CC=C2C=1NC(=O)C(C)CC1=CC=C(Cl)C(Cl)=C1 QPJLXQIFYVOTGJ-UHFFFAOYSA-N 0.000 claims 1
- PXFQSPCEISBBTQ-UHFFFAOYSA-N 6-chloro-2-methyl-n-(2-phenylethyl)quinoline-5-carboxamide Chemical compound ClC=1C=CC2=NC(C)=CC=C2C=1C(=O)NCCC1=CC=CC=C1 PXFQSPCEISBBTQ-UHFFFAOYSA-N 0.000 claims 1
- FKNRDGLGAVYQNE-ZDUSSCGKSA-N 6-chloro-2-methyl-n-[(2r)-2-phenylpropyl]quinoline-5-carboxamide Chemical compound C1([C@H](CNC(=O)C=2C3=CC=C(C)N=C3C=CC=2Cl)C)=CC=CC=C1 FKNRDGLGAVYQNE-ZDUSSCGKSA-N 0.000 claims 1
- FKNRDGLGAVYQNE-CYBMUJFWSA-N 6-chloro-2-methyl-n-[(2s)-2-phenylpropyl]quinoline-5-carboxamide Chemical compound C1([C@@H](CNC(=O)C=2C3=CC=C(C)N=C3C=CC=2Cl)C)=CC=CC=C1 FKNRDGLGAVYQNE-CYBMUJFWSA-N 0.000 claims 1
- CDZVLNSGNDRVKN-KRWDZBQOSA-N 6-chloro-n-[2-(2-chlorophenyl)ethyl]-2-[(3s)-3-(2-hydroxyethylamino)pyrrolidin-1-yl]quinoline-5-carboxamide Chemical compound C1[C@@H](NCCO)CCN1C1=CC=C(C(C(=O)NCCC=2C(=CC=CC=2)Cl)=C(Cl)C=C2)C2=N1 CDZVLNSGNDRVKN-KRWDZBQOSA-N 0.000 claims 1
- IPHOLPIMAJTCJX-UHFFFAOYSA-N 6-chloro-n-[2-(2-chlorophenyl)ethyl]-2-[4-(5-oxo-1h-1,2,4-triazol-4-yl)piperidin-1-yl]quinoline-5-carboxamide Chemical compound ClC1=CC=CC=C1CCNC(=O)C1=C(Cl)C=CC2=NC(N3CCC(CC3)N3C(NN=C3)=O)=CC=C12 IPHOLPIMAJTCJX-UHFFFAOYSA-N 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 claims 1
- XZBIXDPGRMLSTC-UHFFFAOYSA-N formohydrazide Chemical compound NNC=O XZBIXDPGRMLSTC-UHFFFAOYSA-N 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- 238000005984 hydrogenation reaction Methods 0.000 claims 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- JLSUJDXRJOLXMV-UHFFFAOYSA-N n-(6-chloro-2-piperazin-1-ylquinolin-5-yl)-3-(2-methoxyphenyl)propanamide Chemical compound COC1=CC=CC=C1CCC(=O)NC1=C(Cl)C=CC2=NC(N3CCNCC3)=CC=C12 JLSUJDXRJOLXMV-UHFFFAOYSA-N 0.000 claims 1
- FWEPRJAGHDPQGK-UHFFFAOYSA-N n-(6-chloro-2-piperazin-1-ylquinolin-5-yl)-3-phenylpropanamide Chemical compound ClC1=CC=C2N=C(N3CCNCC3)C=CC2=C1NC(=O)CCC1=CC=CC=C1 FWEPRJAGHDPQGK-UHFFFAOYSA-N 0.000 claims 1
- QIPHOMBDWJEGDN-HNNXBMFYSA-N n-[2-[(3s)-3-aminopyrrolidin-1-yl]-6-chloroquinolin-5-yl]-3-(2-chlorophenyl)propanamide Chemical compound C1[C@@H](N)CCN1C1=CC=C(C(NC(=O)CCC=2C(=CC=CC=2)Cl)=C(Cl)C=C2)C2=N1 QIPHOMBDWJEGDN-HNNXBMFYSA-N 0.000 claims 1
- UAVOXGQJGZBOBO-KRWDZBQOSA-N n-[6-chloro-2-[(3s)-3-(2-hydroxyethylamino)pyrrolidin-1-yl]quinolin-5-yl]-3-(2-chlorophenyl)propanamide Chemical compound C1[C@@H](NCCO)CCN1C1=CC=C(C(NC(=O)CCC=2C(=CC=CC=2)Cl)=C(Cl)C=C2)C2=N1 UAVOXGQJGZBOBO-KRWDZBQOSA-N 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000006268 reductive amination reaction Methods 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 claims 1
- 125000004665 trialkylsilyl group Chemical group 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0302139A SE0302139D0 (sv) | 2003-07-28 | 2003-07-28 | Novel compounds |
| SE0302139-1 | 2003-07-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006102127A true RU2006102127A (ru) | 2006-08-27 |
Family
ID=27786663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006102127/04A RU2006102127A (ru) | 2003-07-28 | 2004-07-21 | Производные хинолина и их применение в терапии |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20080058293A1 (enExample) |
| EP (1) | EP1651610A1 (enExample) |
| JP (1) | JP2007500187A (enExample) |
| KR (1) | KR20060054370A (enExample) |
| CN (1) | CN1829694A (enExample) |
| AU (1) | AU2004259615A1 (enExample) |
| BR (1) | BRPI0413094A (enExample) |
| CA (1) | CA2532154A1 (enExample) |
| CO (1) | CO5640110A2 (enExample) |
| IL (1) | IL172826A0 (enExample) |
| IS (1) | IS8329A (enExample) |
| MX (1) | MXPA06000882A (enExample) |
| RU (1) | RU2006102127A (enExample) |
| SE (1) | SE0302139D0 (enExample) |
| WO (1) | WO2005009968A1 (enExample) |
| ZA (1) | ZA200600820B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0312609D0 (en) | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
| WO2006110516A1 (en) * | 2005-04-11 | 2006-10-19 | Abbott Laboratories | Acylhydrazide p2x7 antagonists and uses thereof |
| CA2645556C (en) | 2006-03-16 | 2016-05-24 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| WO2007109160A2 (en) | 2006-03-16 | 2007-09-27 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| US20080058309A1 (en) * | 2006-07-27 | 2008-03-06 | Astrazeneca Ab | Novel Compounds 171 |
| KR20090122396A (ko) * | 2007-03-22 | 2009-11-27 | 아스트라제네카 아베 | 염증성 질환 치료용 퀴놀린 유도체 |
| US8106073B2 (en) | 2007-11-30 | 2012-01-31 | Astrazeneca Ab | Quinoline derivatives 057 |
| ES2357682T3 (es) | 2008-03-25 | 2011-04-28 | Affectis Pharmaceuticals Ag | Antagonistas de p2x7r novedosos y su utilización. |
| CN102395562A (zh) | 2009-04-14 | 2012-03-28 | 阿费克蒂斯制药股份公司 | 新的p2x7r拮抗剂及其用途 |
| ME02421B (me) * | 2009-12-17 | 2016-09-20 | Merck Sharp & Dohme | Pozitivni alosterni modulatori m1 receptora na bazi hinolin amida |
| EP2386541A1 (en) | 2010-05-14 | 2011-11-16 | Affectis Pharmaceuticals AG | Novel methods for the preparation of P2X7R antagonists |
| WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2013014587A1 (en) | 2011-07-22 | 2013-01-31 | Actelion Pharmaceuticals Ltd | Heterocyclic amide derivatives as p2x7 receptor antagonists |
| TWI576347B (zh) | 2012-01-20 | 2017-04-01 | 艾克泰聯製藥有限公司 | 作為ｐ２ｘ受體拮抗劑之雜環醯胺衍生物 |
| PL2931717T3 (pl) | 2012-12-12 | 2017-05-31 | Actelion Pharmaceuticals Ltd. | Pochodne indolokarboksyamidu jako antagoniści receptora p2x7 |
| CN104854087B (zh) | 2012-12-18 | 2017-03-22 | 埃科特莱茵药品有限公司 | 作为p2x7受体拮抗剂的吲哚羧酰胺衍生物 |
| WO2014115078A1 (en) | 2013-01-22 | 2014-07-31 | Actelion Pharmaceuticals Ltd | Heterocyclic amide derivatives as p2x7 receptor antagonists |
| CN104918617B (zh) | 2013-01-22 | 2017-05-10 | 埃科特莱茵药品有限公司 | 作为p2x7受体拮抗剂的杂环酰胺衍生物 |
| EP3152192A1 (en) * | 2014-06-05 | 2017-04-12 | Merck Patent GmbH | Novel quinoline derivatives and their use in neurodegenerative diseases |
| RU2724350C1 (ru) | 2017-03-13 | 2020-06-23 | Раквалиа Фарма Инк. | Производные тетрагидрохинолина в качестве антагонистов рецептора р2х7 |
| CN111777638B (zh) * | 2020-05-22 | 2023-05-09 | 瀚海新拓(杭州)生物医药有限公司 | 喹啉类化合物、其制备方法、药物组合物和用途 |
| CN114989082B (zh) * | 2022-06-30 | 2024-06-21 | 华东理工大学 | 基于i价铜化物和三取代膦协同催化的羟氯喹的高效制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3471491A (en) * | 1967-08-28 | 1969-10-07 | Squibb & Sons Inc | Adamantyl-s-triazines |
| US3464998A (en) * | 1968-03-04 | 1969-09-02 | Searle & Co | Adamantyl esters and amides of pyridinecarboxylic acids |
| US4751292A (en) * | 1985-07-02 | 1988-06-14 | The Plant Cell Research Institute, Inc. | Adamantyl purines |
| ES2099206T3 (es) * | 1991-02-21 | 1997-05-16 | Sankyo Co | Derivados de benceno que favorecen la produccion del factor de crecimiento de los nervios humanos. |
| SK282721B6 (sk) * | 1994-05-27 | 2002-11-06 | Smithkline Beecham S.P.A. | Nepeptidové NK3 antagonistické látky, spôsob ich výroby, farmaceutické prostriedky s ich obsahom a ich použitie |
| AR004735A1 (es) * | 1995-11-24 | 1999-03-10 | Smithkline Beecham Spa | Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento. |
| EP0952832B1 (en) * | 1996-05-20 | 2008-08-27 | Darwin Discovery Limited | Quinoline carboxamides as tnf inhibitors and as pde-iv inhibitors |
| GB0013737D0 (en) * | 2000-06-07 | 2000-07-26 | Astrazeneca Ab | Novel compounds |
| JP4523273B2 (ja) * | 2001-07-02 | 2010-08-11 | ナームローゼ・フエンノートチヤツプ・オルガノン | テトラヒドロキノリン誘導体 |
| SE0103836D0 (sv) * | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Novel compounds |
-
2003
- 2003-07-28 SE SE0302139A patent/SE0302139D0/xx unknown
-
2004
- 2004-07-21 RU RU2006102127/04A patent/RU2006102127A/ru not_active Application Discontinuation
- 2004-07-21 CA CA002532154A patent/CA2532154A1/en not_active Abandoned
- 2004-07-21 MX MXPA06000882A patent/MXPA06000882A/es not_active Application Discontinuation
- 2004-07-21 US US10/566,320 patent/US20080058293A1/en not_active Abandoned
- 2004-07-21 CN CNA2004800220985A patent/CN1829694A/zh active Pending
- 2004-07-21 KR KR1020067001966A patent/KR20060054370A/ko not_active Withdrawn
- 2004-07-21 AU AU2004259615A patent/AU2004259615A1/en not_active Abandoned
- 2004-07-21 WO PCT/SE2004/001144 patent/WO2005009968A1/en not_active Ceased
- 2004-07-21 EP EP04749180A patent/EP1651610A1/en not_active Withdrawn
- 2004-07-21 BR BRPI0413094-4A patent/BRPI0413094A/pt not_active Application Discontinuation
- 2004-07-21 JP JP2006521802A patent/JP2007500187A/ja not_active Withdrawn
-
2005
- 2005-12-26 IL IL172826A patent/IL172826A0/en unknown
-
2006
- 2006-01-25 CO CO06006724A patent/CO5640110A2/es not_active Application Discontinuation
- 2006-01-27 ZA ZA200600820A patent/ZA200600820B/en unknown
- 2006-02-24 IS IS8329A patent/IS8329A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1651610A1 (en) | 2006-05-03 |
| BRPI0413094A (pt) | 2006-10-03 |
| MXPA06000882A (es) | 2006-03-30 |
| ZA200600820B (en) | 2007-04-25 |
| US20080058293A1 (en) | 2008-03-06 |
| JP2007500187A (ja) | 2007-01-11 |
| CN1829694A (zh) | 2006-09-06 |
| KR20060054370A (ko) | 2006-05-22 |
| AU2004259615A1 (en) | 2005-02-03 |
| CO5640110A2 (es) | 2006-05-31 |
| SE0302139D0 (sv) | 2003-07-28 |
| IS8329A (is) | 2006-02-24 |
| IL172826A0 (en) | 2006-06-11 |
| WO2005009968A1 (en) | 2005-02-03 |
| CA2532154A1 (en) | 2005-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006102127A (ru) | Производные хинолина и их применение в терапии | |
| RU2347778C2 (ru) | Новые антагонисты р2х7 рецепторов, способ их получения, фармацевтическая композиция, способ лечения и применение на их основе | |
| RU2333205C2 (ru) | Производные бензотиадиазепина, способ их получения и их применение, фармацевтическая композиция, обладающая ингибирующей активностью в отношении переноса желчных кислот в подвздошной кишке | |
| JP7642707B2 (ja) | カルバモイルフェニルアラニノール類縁体およびその使用 | |
| RU2328494C2 (ru) | Замещенные пиперазины, (1,4)-диазепины и 2,5-диазабицикло[2.2.1]гептаны в качестве н1-и/или н3-антагонистов гистамина или обратных н3-антагонистов гистамина | |
| CN100369894C (zh) | 氧化氮合酶抑制剂磷酸盐 | |
| TWI837169B (zh) | 甲狀腺素受體β促效劑化合物 | |
| JP2005519932A5 (enExample) | ||
| RU2004120553A (ru) | Производные никотинамида, полезные в качестве р38-ингибиторов | |
| JP2007500187A5 (enExample) | ||
| CA2466965A1 (en) | Sulphonamide derivatives, their preparation and use as medicaments | |
| JP2010065041A (ja) | 置換複素環式尿素を用いたｒａｆキナーゼの阻害 | |
| JP2007502804A5 (enExample) | ||
| JPH08504435A (ja) | タキキニン受容体拮抗剤としての４−アミノメチル／チオメチル／スルホニルメチル−４−フェニルピペリジン | |
| RU2005137403A (ru) | Новые замещенные 3-сера-индолы | |
| JP2005509003A5 (enExample) | ||
| RU2005107314A (ru) | Пиримидопроизводные, характеризующиеся антипролиферативной активностью | |
| RU2004135064A (ru) | Новые замещенные индолы | |
| RU2011140064A (ru) | Ингибиторы тирозинкиназы брутона | |
| JP2008509166A5 (enExample) | ||
| HRP20110590T1 (hr) | Spojevi 8-azabiciklo[3.2.1]oktana kao antagonisti mu opioidnih receptora | |
| PE20050420A1 (es) | Fenacilo 2-hidroxi-3-diaminoalcanos | |
| RU2004130426A (ru) | Циклические амиды | |
| JP2011526594A5 (enExample) | ||
| RU98114667A (ru) | 3-азетидинилалкилпиперидины или пирролидины в качестве антагонистов тахикинина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20070823 |